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Objectives: The objective of this study was to inform public health actions to limit first-line ART failure and HIV
drug resistance in Mozambique.
Methods: This was a cross-sectional study. HIV-1-infected adults on first-line ART for at least 1 year attending
routine visits in the Manhic¸a District Hospital, in a semi-rural area in southern Mozambique with no HIV-1 RNA
monitoring available, were evaluated for clinical, socio-demographic, therapeutic, immunological and virological
characteristics. Factors associated with HIV-1 RNA ≥1000 copies/mL and HIV drug resistance were determined
using multivariate logistic regression.
Results: The study included 334 adults on first-line ART for a median of 3 years, of which 65% (214/332)
had suppressed viraemia, 11% (37/332) had low-level viraemia (HIV-1 RNA 150–999 copies/mL) and 24%
(81/332) had overt virological failure (HIV-1 RNA ≥1000 copies/mL). HIV drug resistance was detected in 89%
of subjects with virological failure, but in none with low-level viraemia. Younger age [OR¼0.97 per additional
year (95% CI¼0.94–1.00), P¼0.039], ART initiation at WHO stage III/IV [OR¼2.10 (95% CI¼1.23–3.57),
P¼0.003] and low ART adherence [OR¼2.69 (95% CI¼1.39–5.19), P¼0.003] were associated with virological
failure. Longer time on ART [OR¼1.55 per additional year (95% CI¼1.00–2.43), P¼0.052] and illiteracy
[OR¼0.24 (95% CI¼0.07–0.89), P¼0.033] were associated with HIV drug resistance. Compared with HIV-1
RNA, clinician’s judgement of ART failure, based on clinical and immunological outcomes, only achieved 29%
sensitivity and misdiagnosed 1 out of every 4.5 subjects.
Conclusions: Public health programmes in Mozambique should focus on early HIV diagnosis, early ART initiation
and adherence support. Virological monitoring drastically improves the diagnosis of ART failure, enabling a better
use of resources.
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Introduction
Since 2001 the WHO has promoted the provision of ART following
a public health approach to enable scale-up of access in low-
income countries.1 The use of standardized, affordable and sim-
plified treatment protocols characterized by a limited number of
regimens and decentralized service delivery allowed .9 million
people in low- and middle-income countries to receive ART in
2012, which represents a 30-fold increase since 2003.2
This increase in access to ART for the most vulnerable popu-
lations is accompanied by major challenges. One of the main
difficulties has been in the capacity to follow theWHO recommen-
dations of viral load monitoring for guiding treatment changes.
Indeed, in settings where advanced laboratory infrastructure is
not available, clinical and immunological assessment guides deci-
sions on when to start, stop, substitute and switch ART.3 Although
such an approach has been associated with overall good long-
term clinical outcomes, it may delay the diagnosis of true
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virological failure (VF), preventing the need for treatment switches
to avoid the accumulation of HIV drug resistance mutations
(DRMs) and disease progression.4–7 Continuation on a failing regi-
men may be associated with more complex mutation patterns,
development of cross-resistance to NRTIs and NNRTIs and
onward transmission of drug-resistant HIV to ART-naive patients.
The prevalence of transmitted HIV resistance has recently
increased to 5% in some areas of South Africa, Kenya and
Zambia and has reached .15% in Uganda, representing a
major public health challenge in the control of the HIV epidemic
in sub-Saharan Africa.8–10 It is thus critical to develop informed
strategies to prevent the development of VF to first-line ART and
the emergence of HIV resistance.
Although surveys have been conducted in other countries in
the region, data on ART effectiveness and HIV drug resistance in
adults in Mozambique, a country with one of the highest HIV pre-
valences in the world, are still very limited.11–16 Mozambique has
a long-standing tradition of labour migrants to neighbouring
countries, especially from the southern part of the country to
South Africa. Major transport corridors link inner countries such
as Zimbabwe, Zambia and Malawi to important seaports and
the regional hub of South Africa. As ART coverage continues to
grow, achieving a detailed knowledge of the effectiveness of first-
line ART in Mozambique and its determinants is key to optimizing
programme planning and management. Ultimately, this would
make it possible to protect and extend the benefits of the public
health approach to reducing the HIVepidemic in Mozambique and
other Southern African countries.
Methods
Study area and population
The study was carried out at the outpatient clinic of Manhic¸a District
Hospital. Manhic¸a is a semi-rural area of Maputo Province, southern
Mozambique. The Centro de Investigac¸a˜o em Sau´de de Manhic¸a (CISM)
has been conducting, since 1996, continuous demographic surveillance
in the Manhic¸a District, which covers a population of 95000 inhabitants
in an area of 500 km2. A recent community-based study in adults in the
Manhic¸a area reported nearly 40% HIV prevalence, with 30% HIV preva-
lence among pregnant women attending antenatal clinics.17,18 At the
time of the study, national guidelines recommended zidovudine+
lamivudine+nevirapine as the first ART option. Stavudine was adminis-
tered instead of zidovudine in case of anaemia (haemoglobin ,8 g/dL)
and efavirenz instead of nevirapine if concomitant TB treatment was
needed. Available second-line regimens at the time of the study are listed
in Table S1 (available as Supplementary data at JAC Online). Although roll
out of ART started in Mozambique in 2004, ART coverage among eligible
adults is estimated to be,50%.19 First- and second-line ART is freely pro-
vided, following a population-based model of care. Treatment switches
are guided by clinical and immunological criteria in the absence of viro-
logical monitoring. Standard follow-up of HIV-infected patients on ART
consists of outpatient visits every 6 months, which include physical exam-
ination and CD4+ T cell count, haematology and biochemistry.20
Study design
This was a cross-sectional study conducted among patients attending the
outpatient clinic of the Manhic¸a District Hospital. The study protocol was
approved by the institutional review boards and ethics committees of the
Hospital Clı´nic in Barcelona, the Hospital Germans Trias i Pujol in Badalona,
Spain, and the National Committee on Health Bioethics, Mozambique. All
study participants provided signed informed consent.
Study procedures
Adults ≥18 years of age attending routine scheduled outpatient visits
for clinical management of HIV/AIDS were consecutively recruited for
the study if they had documented HIV infection, documented ART initi-
ation ≥12 months earlier and provided a signed informed consent.
Socio-demographic and clinical data were registered using standardized
questionnaires. Information on HIV diagnosis, ART initiation, line regimen
modifications, treatment withdrawals, TB treatment, suspected treat-
ment failure and clinician-reported low treatment adherence were
obtained from the patient’s medical chart.
A 10 mL blood sample was drawn into EDTA tubes for CD4+ T cell
count, HIV-1 RNAviral load, HIV DRM and nevirapine plasma level determi-
nations. A urine pregnancy test was performed in women of childbear-
ing age.
Laboratory methods
HIV-1 RNA levels were determined from cryopreserved plasma samples
with the Abbott m2000 RealTime System (detection limit 150 copies/mL
for 0.2 mL sample volume). CD4+ T cell counts were determined by flow
cytometry after staining of whole blood for CD3, CD8, CD4 and CD45 using
fluorochrome-labelled antibodies and acquisition using FACSCalibur (BD
Biosciences) and Trucount tubes (Becton Dickinson, San Jose, CA, USA).
Analysis of genotypic drug resistance of plasma HIV was attempted in
all subjects with HIV-1 RNA ≥150 copies/mL. HIV-1 RNA was extracted
from 140 mL of plasma samples (QIAamp Viral RNA Mini Kit, Qiagen).
The pol region was reverse transcribed and amplified in a one-step reac-
tion followed by nested PCR. Nested PCR products were inspected by elec-
trophoresis and positive reactions were column-purified (QIAquick PCR
Purification Kit, Qiagen) for in-house bulk sequencing. Cycling conditions
and primers used for one-step RT–PCR, nested PCR and in-house bulk
sequencing are detailed in Table S2. The fully automated sequence ana-
lysis pipeline RECall was used to analyse sequence chromatograms.21,22
Drug resistance-associated mutations in protease and reverse transcript-
ase gene regions fromall quality-assured sequenceswere interpretedwith
the HIV database (HIVdb) program implemented in the Stanford HIV drug
resistance database web site. To predict susceptibility to NRTIs, NNRTIs
and PIs, the Stanford HIVdb scoring system was applied and a resistance
score was calculated as susceptible, potentially low level, low level, inter-
mediate level and high level (http://hivdb.stanford.edu). Nevirapine con-
centrations in plasma were determined by HPLC.
Statistical methods and definitions
Malnutrition was defined as a BMI,18.5 kg/m2. Suspected treatment fail-
ure was defined as reported clinician’s judgement of treatment failure
based on clinical and immunological failure specified in Mozambican
guidelines. Immunological failure was defined as CD4+ T cell counts
lower than the pre-ART count, or ,50% of the highest value achieved
after initiating ART, or ,100 cells/mm3 after being on ART for at least
1 year. Clinical failure was defined as a new or recurrent clinical event indi-
cating WHO clinical stage IV after 6 months of ART.20 Low ART adherence
was defined as the presence of at least one of the following: self-reported
low adherence, clinician-reported low adherence or previous voluntary
treatment withdrawal. Self-reported low adherence was defined as the
patient’s confirmation of at least one missed dose of ART in the 7 days
before the study survey. Clinician-reported low adherence and treatment
withdrawals were defined according to missing on-time ART drug pickups
on pharmacy records. ART modification refers to changes in one drug
in the regimen within the same first-line ART approach. Treatment
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withdrawal was defined as the interruption of ART drug pickups for at
least 2 months.20 Detectable viral load was defined as HIV-1 RNA levels
≥150 copies/mL and VF as HIV-1 RNA ≥1000 copies/mL. Viral load
between 150 and 999 copies/mL was defined as low-level viraemia
(LLV). Severe immune depression was defined as a CD4+ T cell count
≤200 cells/mm3. HIV drug resistance was considered as the presence of
one or more major resistance mutations as defined by the Stanford HIV
DRM database (http://hivdb.stanford.edu).
Baseline characteristics of study patients were described using stand-
ard statistics. Associations between socio-demographic and HIV-related
variables and each of the primary outcomes (VF and presence of HIV
DRMs) were assessed using the x2 test for categorical variables and
Student’s t-test or the Mann–Whitney test for continuous variables, as
required. To measure the association of variables with primary outcomes,
all variables with evidence of association in the univariate analysis (differ-
ent OR for different categories and a P value ,0.15) were included in a
multiple logistic regression analysis. Pooled P values were obtained for cat-
egorical variables throughWald tests or likelihood ratio tests depending on
the need for adjustment of correlated data. Bothmultivariate analyses for
VF and HIV DRMs were adjusted by CD4+ T cell counts and suspected
treatment failure. The HIV resistance model was also adjusted for VF.
Statistical analyses were performed using Stata 12TM software (Stata
Corp., Houston, TX, USA).
Results
Characteristics of the study patients
There were 334 patients enrolled between February and March
2013. Most of them were women (70%), median age was
39 years (IQR 33–48), median time on ART was 3.2 years (IQR
2.0–5.2) and 90% were receiving zidovudine/lamivudine/nevira-
pine at the time of the survey. Overall only 37% (125/334) had
a primary education level, 32% (106/334) had no schooling and
34% (115/334) were illiterate. Forty-three per cent of subjects
(144/334) initiated ART in WHO stage III/IV. Malnutrition was
observed in 8% (26/334) of the subjects. Eleven per cent
(38/334) had had concomitant TB treatment while receiving
ART, whereas 23% (53/232) of women became pregnant during
ART. Sixteen per cent (52/334) had estimated low adherence
at the time of the survey and 13% (44/334) reported previous
ART withdrawals. According to the clinician’s judgement, 12%
(39/334) of subjects had suspected ART failure (Table 1).
Immunological status
Two thirds of subjects (220/332) had CD4+ counts.350 cells/mm3
and 40% (134/332) had .500 cells/mm3 at the time of the
study (Table 1). Severe immune suppression was observed in
16% (52/332) of the subjects and it was more frequent among
male subjects in the univariate analysis [OR¼1.83 (95%
CI¼1.00–3.37), P¼0.05].
VF
Of the 332 subjects assessed for HIV-1 RNA levels, 118 (36%) had
detectable viraemia, 37 (11%) had LLV and 81 (24%) had VF
(Table 1). HIV-1 RNA levels were missing for two patients.
Undetectable nevirapine concentrations were found in 9/103
(9%) of the patients in whom nevirapine plasma levels were mea-
sured, 8 of whom had HIV-1 RNA ≥1000 copies/mL. Severe
immune suppression [OR¼22.4 (95% CI¼10.6–47.1), P,0.001]
and suspected treatment failure [4.2 (95% CI¼2.5–8.7),
P,0.001] were significantly associated with VF, but, due to
co-linearity with the primary endpoint, they were not included in
the multivariate model. Factors associated with VF included initi-
ation of ART at WHO stage III/IV [OR 2.10 (95% CI¼1.23–3.57),
P¼0.003], younger age [OR 0.97 per additional year (95%
CI¼0.94–1.00), P¼0.039] and estimated low adherence [OR
2.69 (95% CI¼1.39–5.19), P¼0.003] (Table 2).
HIV drug resistance
Genotyping resistance data were obtained from 61/81 (75%)
and 11/37 (30%) of subjects with VF and LLV, respectively
(Table 3). HIV DRMs were only detected in subjects with HIV-1
RNA ≥1000 copies/mL. Of these, 89% had at least one HIV DRM.
Out of 61 subjects, 54 (89%) presented mutations conferring
resistance to NNRTIs and 49 (80%) presented mutations confer-
ring resistance to NRTIs, always alongside NNRTI resistance
mutations. As expected, no PI resistance was detected. The
most common mutations were 184V, which was present in
45/72 individuals (63%), followed by 103N, 190A and 181C,
found in 20/72 (28%), 19/72 (26%) and 16/72 (22%) subjects,
respectively (Table S3). The phenotypic impact of the available
genotypes is shown in Figure 1. Of note, no HIV DRMs were
found in the 11 subjects with LLV and available genotypic data.
Factors associated with HIV DRMs were longer time on ART
[OR¼1.55 per additional year (95% CI¼1.00–2.43), P¼0.052]
and illiteracy [OR¼0.24 (95%CI¼0.07–0.89), P¼0.033] (Table 2).
Performance of clinician’s judgement for predicting VF
The clinician’s judgement of treatment failure, based on clinical
and immunological criteria, had a sensitivity of 29% for predicting
treatment failure, detecting only 22 out of the 76 cases with
confirmed VF (HIV-1 RNA ≥1000 copies/mL), and thus leaving
.70% of the patients in need without a required ART change
(Table S4). Specificity was 94% (243/260). Positive predictive
value was 56% (22/39), and thus 44% of the patients who
were classified by the clinician as having treatment failure had
HIV-1 RNA ,1000 copies/mL and the premature change of ART
in them could have been avoided. The number of patients needed
to misdiagnose was 4.5, meaning that 1 out of every 4.5 subjects
evaluated for the presence of ART failurewasmisdiagnosed in one
direction or another (Table S4).
Discussion
This cross-sectional study among HIV-infected adults attend-
ing the outpatient clinic of a district hospital in southern
Mozambique showed that two-thirds of the subjects retained
undetectable HIV-1 RNA levels after 3 years of first-line ART.
Overt VF was observed in a quarter of subjects, whereas LLV
was found in 11%. The main determinants of VF were younger
age, having a WHO III/IV stage at ART initiation and the presence
of estimated low adherence to ART. VF had serious consequences,
as almost 90% of subjects with HIV-1 RNA ≥1000 copies/mL
had developed resistance to first-line treatment options.
Literacy and years on ART were associated with the presence of
HIV DRMs. However, in this study HIV resistancewas only observed
in subjects with HIV-1 RNA ≥1000 copies/mL. This suggests that
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Table 1. Study population characteristics
Socio-demographic characteristics
Age (years), median (IQR) 39 (33–48)
Women, n (%) 232 (69.5)
Civil status single, n (%) 38 (11.6)
widow, n (%) 63 (19.2)
divorced, n (%) 25 (7.6)
married/union, n (%) 202 (60.5)
Educationa no schooling, n (%) 106 (31.8)
primary education, n (%) 125 (37.5)
secondary education, n (%) 99 (29.7)
higher education, n (%) 3 (0.9)
Literacy (able to read and write) yes, n (%) 219 (65.6)
no, n (%) 115 (34.4)
HIV and ART-related characteristics
At the time of first-line ART initiation age (years), median (IQR) 36.2 (29.7–44.6)
time since HIV diagnosis (months), median (IQR) 4.8 (1.9–16.6)
WHO clinical stage of HIV/AIDS, n (%)
I/II 188 (56.6)
III/IV 144 (43.4)
starting ART, n (%)
d4T+3TC+NVP 157 (47.0)
ZDV+3TC+NVP 153 (45.8)
d4T+3TC+EFV 14 (4.2)
ZDV+3TC+EFV 10 (3.0)
At the time of the survey malnutrition (BMIb ,18.5 kg/m2), n (%) 26 (7.8)
any type of symptoms, n (%) 125 (37.4)
time on ART (years), median (IQR) 3.2 (2.0–5.2)
time since HIV diagnosis (years), median (IQR) 4.8 (2.9–6.4)
at least one previous ART modificationc, n (%) 184 (55.1)
current ART, n (%)
ZDV+3TC+NVP 299 (89.5)
d4T+3TC+NVP 28 (8.4)
ZDV+3TC+EFV 6 (1.8)
d4T+3TC+EFV 1 (0.3)
women pregnant while on ART, n (%) 53 (22.8)
TB treatment while on ART, n (%) 38 (11.4)
suspected ART failure, n (%) 39 (11.7)
previous ART withdrawals, n (%) 44 (13.2)
self-reported low adherence, n (%) 11 (3.3)
recorded low adherence, n (%) 11 (3.3)
estimated low adherenced, n (%) 52 (15.6)
therapeutic NVP plasma levelse, n (%) 94 (91.3)
HIV-1 RNA (copies/mL), n (%)
≤150 214 (64.5)
150–999 37 (11.1)
≥1000 81 (24.4)
CD4+T cell count (cells/mm3), n (%)
≤50 12 (3.6)
51–200 40 (12.0)
201–350 60 (18.1)
351–500 86 (25.9)
.500 134 (40.4)
ZDV, zidovudine; 3TC, lamivudine; NVP, nevirapine; d4T, stavudine; EFV, efavirenz.
aPrimary education comprises seven grades of elementary education at primary school. Secondary education comprises four grades of pre-university
education. Higher education refers to acquisition of a university degree.
bWeight (kg)/height (m)2.
cRefers to changes in one drug in the regimen within the same first-line ART approach.
dEstimated low adherence if positive answer in at least one of the three preceding fields on adherence (ART withdrawals, self-reported low adherence
and recorded low adherence).
eSub-sample of 103 subjects.
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Table 2. Factors associated with VF and with the presence of at least one DRM at VF
Variable
VF HIV drug resistance
univariate analysis multivariate analysisa univariate analysis multivariate analysisa
OR 95% CI P AOR 95% CI P OR 95% CI P AOR 95% CI P
Age at time of study evaluation, per each additional year 0.98 0.95–1.00 0.063 0.97 0.94–1.00 0.039 0.97 0.92–1.02 0.251 — — —
Male 1.09 0.64–1.87 0.758 — — — 2.23 0.56–8.77 0.253 — — —
No schooling 0.95 0.55–1.63 0.849 — — — 0.47 0.15–1.47 0.195 — — —
Illiteracy (not able to read or write) 1.01 0.70–1.72 0.960 — — — 0.31 0.10–0.98 0.045 0.24 0.07–0.89 0.033
Years on ART, per additional year 1.07 0.94–1.22 0.314 — — — 1.46 1.00–2.14 0.051 1.55 1.00–2.43 0.052
Years since HIV diagnosis, per additional year 1.01 0.89–1.14 0.937 — — — 1.07 0.78–1.47 0.664 — — —
Age at ART initiation, per additional year 0.97 0.95–1.00 0.040 — — — 0.96 0.91–1.01 0.145 — — —
Months between HIV diagnosis and ART, per additional month 0.99 0.97–1.00 0.182 — — — 0.95 0.92–1.00 0.029 — — —
WHO stage III/IV at ART initiation 1.83 1.10–3.05 0.019 2.10 1.23–3.57 0.003 1.73 0.54–5.51 0.354 — — —
Malnutrition (BMIb ,18.5 kg/m2) 2.21 0.95–5.16 0.064 — — — 2.14 0.24–18.84 0.492 — — —
Any symptoms at the time of the survey 1.38 0.83–2.29 0.220 0.56 0.18–1.75 0.317 — — —
At least one previous ART modification 1.30 0.78–2.19 0.308 — — 1.89 0.61–5.85 0.266 — — —
Women pregnant while on ART 1.40 0.70–2.83 0.344 — — — 3.75 0.42–33.63 0.238 — — —
Concomitant TB treatment 1.81 0.87–3.74 0.110 — — — 0.84 0.15–4.63 0.841 — — —
Estimated low adherence 2.73 1.47–5.09 0.001 2.69 1.39–5.19 0.003 1.20 0.34–4.28 0.779 — — —
Starting with ZDV/3TC/NVP versus d4T/3TC/NVP 0.71 0.42–1.20 0.206 0.54 0.18–1.82 0.346 — — —
Current ART with ZDV/3TC/NVP versus d4T/3TC/NVP 0.50 0.22–1.10 0.086 0.39 0.05–3.39 0.395 — — —
AOR, adjusted OR; ZDV, zidovudine; 3TC, lamivudine; NVP, nevirapine; d4T, stavudine.
AOR and corresponding 95% CI and P value are only shown for those variables showing a significant association with VF in the multivariate analysis.
aVariables included in the multivariate analysis had P values ,0.15 in the univariate analysis.
bWeight (kg)/height (m)2.
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subjects with LLV may have a window of opportunity to re-
suppress viral replication through adherence interventions,
whereas those with overt VF should be switched to second-line
ART without further delay. Of note, the clinician’s judgement
of ART failure, based on immunological and clinical criteria cur-
rently in place for patient management, was extraordinarily
inaccurate in predicting VF, highlighting the urgent need for
fostering point-of-care virological monitoring tools for low-
income countries.
To our knowledge, this is the first comprehensive, well-powered
study addressing the clinical and virological determinants of VF in
Mozambique. Previous studies in the country were conducted
before or at the beginning of the ART rollout, providing little infor-
mation on the effectiveness of ART, or did not evaluate the deter-
minants of virological outcomes of first-line ART.11–16 Both are
essential for guiding healthcare policies to improve the effective-
ness of therapy and to prevent resistance emergence, most par-
ticularly if virological monitoring is not available.
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Figure 1. Predicted NRTI and NNRTI susceptibility according to the Stanford HIVdb. 3TC, lamivudine; FTC, emtricitabine; ABC, abacavir; ZDV, zidovudine;
d4T, stavudine; ddI, didanosine; TDF, tenofovir disoproxil fumarate; EFV, efavirenz; NVP, nevirapine; ETR, etravirine; RPV, rilpivirine.
Table 3. Prevalence of DRMs in subjects with detectable viraemia (HIV-1 RNA ≥150 copies/mL)
Viral load (copies/mL)
Subjects with
genotypic
resistance data
available
At least
one DRM
At least one
NNRTI DRM
At least one
NRTI DRM
At least one
NNRTI DRM plus
one NRTI DRM
At least one
PI DRM
n/N % n/N % n/N % n/N % n/N % n/N %
Overall (≥150) 72/118 61.0 54/72 75.0 54/72 75.0 49/72 68.1 49/72 68.1 0 0.0
150–999 11/37 29.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
≥1000 61/81 75.3 54/61 88.5 54/61 88.5 49/61 80.3 49/61 80.3 0 0.0
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The participants in this study were HIV-infected subjects
attending scheduled visits at the outpatient clinic in Manhic¸a
District Hospital. The selection criteriamight have led to the exclu-
sion of those patients who had poorer ARTadherence, individuals
skipping the scheduled control visits due to severe illness or hos-
pital admittance, or those deceased during early ART. On the
other hand, the availability of only one HIV-1 RNA measurement
might have inflated the number of cases of detectable viraemia,
particularly those with HIV-1 RNA ,1000 copies/mL. However,
detection rates of HIV DRMs would have increased if ultra-
sensitive HIV-1 drug resistance testing had been used.23 The lim-
ited number of genotypes available for subjects with LLV limits our
ability to generalize our results in this subset of patients. Though
the clinician’s judgement on ART treatment failure was presum-
ably based on the patient’s clinical and immunological outcomes
as recommended in national guidelines, information on the CD4+
T cell counts and clinical staging that supported this judgement is
not provided. This poses a limitation when interpreting the per-
formance of clinical and/or immunological criteria to predict
treatment failure.
The rates of VFobserved in this studymet theWHO recommen-
dations for the prevention of HIV DRMs (.70% of subjects with
HIV-1 RNA ,1000 copies/mL after at least 1 year of first-line
ART)24 and were consistent with those from neighbouring coun-
tries.8,25–27 However, more VFs were observed in this study than
in the only other similar report from Mozambique, a cross-
sectional study conducted in 2009 on 149 patients on first-line
ART for a median of 23 months, attending the Maputo Central
Hospital, which showed a prevalence of VF of 10%. In comparison
with this study, our cohort included a larger sample size and sub-
jects had been on first-line ART for a longer time.14
Of note, this is the first known study evaluating the rates of LLV
in Southern Africa. The findings from this study showed that
10% of subjects under first-line ART for 3 years have LLV, con-
cordant with data from low- and middle-income countries
in Asia and the Pacific region.28 The clinical implications
and management consequences of LLV remain unclear. First,
the risk of HIV transmission and disease progression is very low
(,1000 copies/mL).29,30 Second, viral blips and intermittent low
viraemia may not be necessarily associated with an increased
risk of treatment failure. On this basis, WHO’s recent consolidated
guidelines recommend reducing the viral load threshold defining
treatment failure from 5000 to 1000 copies/mL.3 This may not
be low enough in view of studies in industrialized settings that
have shown that LLV is associated with increased risk of overt
VF and, in some cases, also with antiretroviral drug resist-
ance.31 –37 In this study, all resistance mutations were found
exclusively in subjects with HIV-1 RNA levels ≥1000 copies/mL.
This is likely related to the high levels of estimated adherence in
the population evaluated, which were further supported by the
presence of therapeutic nevirapine plasma levels in .90% of
the participants tested. Considering the small sample size
of subjects with LLV with an available genotype, we cannot con-
clude that resistance cannot occur below 1000 copies/mL. Thus,
LLV might be able to regain HIV-1 RNA suppression with the
same first-line ART through intensified adherence interventions.
Evidence addressing the clinical and virological implications of
LLV in Africa is urgently needed.
The main factors predicting VF were having a WHO III/IV
stage of HIV disease at ART initiation, being younger and
having a low estimated adherence, consistent with previous
studies.26,27,34,38–41 Initiation of ART at a late stage of disease is
common in sub-Saharan Africa, where high rates of attrition due
to delays or failure to complete ART eligibility assessments have
been described.42 In this study, subjects who initiated ART at
WHO III/IV stages were twice as likely to have CD4+ T cell counts
≤200 cells/mm3 at the time of the survey, which is consistent with
previous reports.43,44 It has also been shown that initiating ARTat
WHO III/IV stages leads to mortality of up to 80% in the first
6 months of therapy;44 these early deaths would not be reflected
in our survey. In agreement with previous studies, both in indus-
trialized and low-income countries , younger age predicted VF,
likely because older age protected against low adherence
[OR¼0.96 (95% CI¼0.93–0.99), P¼0.011].34,45
VF has severe consequences. As seen in other studies in the
sub-Saharan region,26,27,46,47almost 80%of subjects with detect-
able viraemia (90% of those with HIV-1 RNA ≥1000 copies/mL)
had lost most first-line drug options available. Resistance to
second-generation NNRTIs was present in 50% of subjects with
detectable viraemia, limiting their use as second-line ART in the
absence of previous genotypic resistance testing. The NRTI back-
bonewas involved inmost patients, except for tenofovir disoproxil
fumarate, to which susceptibility was retained in 70% of sub-
jects. Based on our results, second-line ART in Mozambique
must thus rely on ritonavir-boosted PIs plus tenofovir disoproxil
fumarate and usually lamivudine. Despite the overall high effect-
iveness of second-line ARTwith boosted PIs in the field, recent evi-
dence that PI monotherapy performs less well than triple-drug,
PI-including ART suggests that the residual activity of the NRTI
backbone is important for the long-term efficacy of second-line
ART.48 Newdrugs with complementary resistance profiles and for-
mulations with enhanced pharmacokinetic properties are
urgently needed to construct effective second-line ART in low-
income settings.
The 2013 WHO consolidated antiretroviral guidelines recom-
mended, for the first time, viral load monitoring as the preferred
monitoring approach to the diagnosis and confirmation of
ART failure. Although efforts are being made to adopt these
guidelines in sub-Saharan Africa, this option still remains largely
out of reach, forcing programmes to rely on clinical outcomes
and CD4+ T cell counts for monitoring treatment efficacy.
This study suggested that clinical and immunological criteria
have extremely poor performance in the diagnosis of treatment
failure. The clinician’s judgement, based on such criteria, missed
almost 75% of VF and erroneously classified 50% of cases as
treatment failure. One out of every four subjects evaluated
in the clinic was misclassified in terms of their actual viro-
logical status. Point-of-care virological monitoring is therefore
essential for early detection of treatment failure to guide
the clinical management of HIV-infected individuals, limit
the emergence of resistance, preserve the effectiveness of
second-line regimens and avoid unnecessary costly treatment
switches.
Ending the HIV/AIDS pandemic will require further efforts to
strengthen healthcare programmes and health systems. The
focus must be placed on ensuring universal and prompt HIV test-
ing and linkage with care, avoiding delays in ART initiation, reinfor-
cing adherence interventions, particularly in younger subjects,
and in developing and widely implementing affordable HIV-1
RNA monitoring.
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